{"title":"Shire以42亿美元收购ViroPharma推进罕见病战略","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I11.1993","DOIUrl":null,"url":null,"abstract":"In order to attain a dominant position in the hereditary angioedema (HAE) market and to increase the size of its rare disease business unit, Shire has agreed to acquire ViroPharma for approximately US$4.2 B in cash. With the acquisition, Shire will gain Cinryze® (C1 esterase inhibitor [human]), a prophylactic HAE treatment that will complement its existing portfolio product Firazyr® (icatibant), which is indicated for acute HAE attacks. The acquisition also offers Shire the potential for annual cost synergies of approximately US$150 M by 2015 and sizeable tax savings.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"7 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Shire Progresses Rare Disease Strategy with US$4.2 B ViroPharma Purchase\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I11.1993\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In order to attain a dominant position in the hereditary angioedema (HAE) market and to increase the size of its rare disease business unit, Shire has agreed to acquire ViroPharma for approximately US$4.2 B in cash. With the acquisition, Shire will gain Cinryze® (C1 esterase inhibitor [human]), a prophylactic HAE treatment that will complement its existing portfolio product Firazyr® (icatibant), which is indicated for acute HAE attacks. The acquisition also offers Shire the potential for annual cost synergies of approximately US$150 M by 2015 and sizeable tax savings.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"7 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-11-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I11.1993\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I11.1993","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Shire Progresses Rare Disease Strategy with US$4.2 B ViroPharma Purchase
In order to attain a dominant position in the hereditary angioedema (HAE) market and to increase the size of its rare disease business unit, Shire has agreed to acquire ViroPharma for approximately US$4.2 B in cash. With the acquisition, Shire will gain Cinryze® (C1 esterase inhibitor [human]), a prophylactic HAE treatment that will complement its existing portfolio product Firazyr® (icatibant), which is indicated for acute HAE attacks. The acquisition also offers Shire the potential for annual cost synergies of approximately US$150 M by 2015 and sizeable tax savings.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
